Hansoh BioMedical R&D Company clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   HS-20093 Versus Gemcitabine in Combination With Docetaxel…HS-20093 Versus Gemcitabine in Combination With Docetaxel · Osteosarcoma After Previous Second-line Treatment Failure

   Trial completed

   Also in this update: Study completion date changed from estimate of Oct 31, 2027 to Sep 7, 2026; and 1 more change in the last 30 days

   Hansoh BioMedical R&D Company·Phase 3· NCT06935409· Registry history of NCT06935409 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

2. Minor

   ARTEMIS-008：HS-20093 Compared With Topotecan · Relapsed Small…ARTEMIS-008：HS-20093 Compared With Topotecan · Relapsed Small Cell Lung Cancer

   Trial completed

   Also in this update: Primary completion date changed from estimate of Sep 30, 2026 to Aug 20, 2026

   Hansoh BioMedical R&D Company·Phase 3· NCT06498479· Registry history of NCT06498479 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.